InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. Conference Call […]

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Quoin Pharmaceuticals, Inc. Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offering, with net proceeds of approximately $15.0 million ASHBURN, Va., Aug. 18, […]

Subscribe US Now